Back to All Topics
Research
Research Article
2 min read
Hunger Hormone Modulation
How peptides interact with ghrelin, leptin, and other appetite-regulating hormones.
Backed by 7 references
Introduction
Several research peptides act on ghrelin, the main hunger hormone (see our appetite regulation overview).
Key Hunger Hormones
Ghrelin (Hunger Hormone)
| Factor | Effect | Peptide Interaction |
|---|---|---|
| Elevated levels | Increased hunger | GHRP-6 mimics it |
| Reduced levels | Decreased hunger | Little peptide data |
| Timing | Rises before meals | Follows meal schedule |
| Bodyweight regulation | Complex role | Still debated |
Leptin (Satiety Hormone)
| Factor | Effect | Considerations |
|---|---|---|
| Elevated levels | Reduced hunger | Resistance can develop |
| Low levels | Increased hunger | Dieting concern |
| Peptide effects | Generally minimal direct | Indirect via composition |
Peptide Effects on Appetite
GH Secretagogues
| Peptide | Appetite Effect | Mechanism | Evidence |
|---|---|---|---|
| GHRP-6 | Strong increase | Ghrelin mimetic | User reports |
| GHRP-2 | Moderate increase | Ghrelin receptor agonist | Human studies |
| Ipamorelin | Minimal effect | Selective GH release | No human data found |
| Hexarelin | Moderate increase | Similar to GHRP-6 | Rat studies |
Fat Loss Peptides
| Peptide | Appetite Effect | Evidence |
|---|---|---|
| Fragment 176-191 | Neutral | Mostly studied as AOD-9604 |
| Tesamorelin | Minimal | Approved for HIV lipodystrophy only |
| Melanotan II | Appetite suppression | Small trials only |
| AOD-9604 | Neutral | Failed human trials |
FDA's 2024 review found most AOD-9604 trials no better than placebo; see our AOD-9604 profile.
GLP-1 Drugs
Prescription semaglutide lowers calorie intake, likely via appetite (Wegovy label). As of October 2026, FDA has approved the Wegovy pill (December 2025) and Wegovy HD (7.2 mg weekly, March 2026); see satiety enhancement.
Strategic Use
These are user practices, not tested protocols.
For Bulking
| Strategy | What users report |
|---|---|
| Appetite-stimulating peptides | GHRP-6 before meals |
| Timing | 30 minutes before meals |
| More hunger | Easier caloric surplus |
For Cutting
| Strategy | What users report |
|---|---|
| Skipping GHRP-6 | Switching to ipamorelin |
| Dosing away from meals | Less noticeable hunger |
| Appetite suppressants | If hunger is a problem |
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- Ghrelin (Müller et al., Molecular Metabolism, 2015)
- Ipamorelin, the first selective growth hormone secretagogue (Raun et al., European Journal of Endocrinology, 1998)
- FDA Pharmacy Compounding Advisory Committee briefing on AOD-9604 (FDA, December 2024)
- FDA approves Wegovy pill for obesity (Novo Nordisk press release, December 2025)
- FDA approves higher-dose semaglutide, Wegovy HD (FDA press announcement, March 2026)
- Wegovy (semaglutide) injection and tablets prescribing information (FDA, 2026)
- Egrifta WR (tesamorelin) prescribing information (FDA, 2025)